AFT Pharmaceuticals (ASX:AFP) has won a significant legal battle, with the New Zealand Court of Appeal dismissing an appeal by PBL Solutions regarding profit-sharing arrangements for the topical skin medicine Pascomer. The ruling centers on the commercialization of Pascomer for the treatment of Port Wine Stains (PWS), a condition outside the scope of “orphan” drug applications. This decision reinforces AFT’s control over the potentially lucrative PWS market and provides clarity for investors regarding future revenue streams.
The dispute arose from a 2023 High Court ruling that initially sided with AFT Pharmaceuticals, finding that PBL Solutions was not entitled to a share of profits generated from Pascomer’s use in treating PWS. PBL Solutions, a 35% shareholder in AFT Orphan Pharmaceuticals, argued that it should receive a portion of the revenue from all applications of Pascomer, including those beyond rare disease indications. The Court of Appeal’s decision upholds the earlier ruling, confirming that profit-sharing with PBL remains limited to orphan drug applications – treatments for rare diseases – and does not extend to the more common PWS condition.
Pascomer has demonstrated promise in treating facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC), an orphan indication, as well as PWS birthmarks, according to AFT Pharmaceuticals. The market for PWS is considerably larger than that for FA, representing approximately 36 times the potential patient base. This difference in market size was a key factor in the legal dispute, as PBL Solutions sought to benefit from the broader commercial opportunities presented by the PWS application.
Understanding the Core of the Dispute
The core of the legal battle revolved around the interpretation of the agreement between AFT Pharmaceuticals and PBL Solutions concerning AFT Orphan Pharmaceuticals. PBL Solutions, linked to a former contractor of AFT Pharmaceuticals, holds a 35% stake in the subsidiary. The disagreement stemmed from whether the development and commercialization of Pascomer for PWS fell within the scope of AFTO’s business and therefore entitled PBL to a share of the profits. The courts have consistently ruled that it did not.
AFT Pharmaceuticals confirmed that it will continue to provide PBL Solutions with 35% of profits earned from Pascomer’s use in orphan drug applications. The company also stated that it will share the costs associated with the appeal process. Importantly, AFT Pharmaceuticals does not anticipate any material impact on its FY 2026 earnings guidance, which currently projects an operating profit between $20 million and $24 million. This stability is largely attributed to the favorable court outcome and the continued growth potential of Pascomer in both orphan and non-orphan indications. Capital Brief reports on the details of the ruling.
Implications for AFT Pharmaceuticals and Investors
This legal victory is a positive development for AFT Pharmaceuticals, solidifying its control over the commercialization of Pascomer for PWS. The ruling provides greater certainty regarding future revenue streams and allows the company to fully capitalize on the larger market opportunity presented by this indication. With a current market capitalization of A$307.7 million, according to TipRanks, AFT Pharmaceuticals is well-positioned to continue its growth trajectory.
The company’s broad portfolio of medicines, spanning over-the-counter, prescription, and hospital channels, and its extensive distribution network reaching over 125 countries, further contribute to its strong market position. AFT Pharmaceuticals’ average trading volume is 1,508, and currently holds a “Strong Buy” technical sentiment signal.
Looking ahead, AFT Pharmaceuticals will continue to focus on the development and commercialization of its existing product pipeline, as well as exploring new opportunities for growth. The company’s commitment to innovation and its strategic partnerships will be crucial in driving future success. The resolution of this profit-sharing dispute allows AFT Pharmaceuticals to concentrate its resources on maximizing the potential of Pascomer and other key products.
Disclaimer: This article provides informational content only and should not be considered financial or medical advice. Consult with a qualified professional for personalized guidance.
What are your thoughts on this ruling and its potential impact on AFT Pharmaceuticals? Share your insights in the comments below.
